| INTRODUCTION
Smith-Kingsmore syndrome (SKS) (MIM 616638), also known as MINDS (ORPHA 457485), is a rare syndrome, first described by Smith et al 1 and caused by mutations in the mammalian target of rapamycin (mTOR, MIM 601231) gene. The most consistent findings in SKS are intellectual disability (ID), developmental delay, megalencephaly and seizures (Table 1 ). There is moderate clinical variability, ranging from patients with macrocephaly, mild ID, and no convulsions, to severe forms in patients with intractable epilepsy, megalencephaly, severe ID, and autistic spectrum disorder (ASD). Other nonneurological features include facial dysmorphisms and small thorax.
SKS belongs to the group of "mTORopathies," a term introduced to describe neurological disorders characterized by altered cortical architecture, abnormal neuronal morphology and intractable epilepsy as a consequence of mTOR signalling hyperactivation, providing probably a histopathological substrate for epileptogenesis. 2, 3 These mTORopathies-related epilepsies include: SKS, isolated hemimegalencephaly, ganglioglioma, focal cortical dysplasia (FCD), and tuberous sclerosis complex (TSC). 2, 4 Macrocephaly and hemi/megalencephaly-with or without normal cortex-is a rather prevalent clinical feature among different types of vascular and/or overgrowth syndromes caused by germline or post-zygotic mutations in different genes in the PI3K-AKT-mTOR pathway:
megalencephaly-polymicrogyria-polydactyly-hydrocephalus syndrome (AKT3 and PIK3R2), 5, 6 megalencephaly-capillary malformation (MCAP; PIK3CA), 7 Bannayan-Riley-Ruvalcaba syndrome (PTEN), 8 Tenorio syndrome (RNF125), 9 isolated hemimegalencephaly (PIK3CA and AKT3), 10 and with syndromes with epilepsy, hemimegalencephaly and/or FCD due to mutations in DEPDC5, NPRL2 and NPRL3 genes, involved in mTORC1 regulation. 11 Axial skeletal overgrowth is not affected by mutations in mTOR, but megalencephaly is clearly a finding. 12 The main differences between the syndromes involved in this pathway are based on: (1) its germinal or somatic origin, causing generalized or segmental distribution patterns as in hemi or megalencephaly, (2) the degree of mosaicism, and (3) the presence of distinctive extra-cerebral manifestations, mostly the vascular malformations, nevi, and adipose overgrowth frequently found in the PIK3CA-related overgrowth spectrum (PROS). 10, [13] [14] [15] The mTOR gene is a key regulator of cell growth, cell proliferation, protein synthesis and synaptic plasticity. The mTOR pathway is highly regulated and critical for cell survival and apoptosis. It is known that mTOR negatively regulates autophagy in response to growth factors, nutritional status and stress responses. Thus, it would appear that impaired autophagy in neurons is directly related to unregulated expression of mTOR and that this plays some role in epilepsy.
12 mTORC1 inhibitors, including drugs currently approved for a variety of conditions, are clinically available inducers of autophagy.
The prevalence of SKS, with 23 patients reported so far, is still unknown. We here report on 4 new SKS patients with mTOR mutations and review all the clinical characteristics and molecular aspects of this disorder. We also discuss some characteristics of patients with brain somatic mutations in mTOR who show some similarities with individuals with SKS. with clinical diagnosis of macrocephaly-capillary malformation.
To update the phenotype in SKS, we performed a retrospective review of the clinical characteristics including the 4 patients described herein, and the 23 patients previously reported to date (Table 2 ). These patients were ascertained from a series of patients with focal epilepsy, ID, brain anomalies and megalencephaly or hemimegalencephaly. 1, 12, [17] [18] [19] [20] [21] [22] Reported patients with only brain somatic mutations of mTOR were also reviewed.
10,17,23-25
| NGS studies
Genomic DNA was extracted from peripheral blood lymphocytes from all patients. DNA was also extracted from saliva, hyperpigmented skin and hypopigmented skin samples from Patient 2.
A deep Next Generation Sequencing (NGS) panel, with an average expected reading depth of ×500, was designed to study 20 genes known to cause developmental syndromes characterized by overgrowth and/or vascular anomalies in the form of somatic mosaicism: NRAS, AKT3, PIK3CA, FGFR3, RASA1, TSC1, GNAQ, PTEN,   HRAS, PTPN11, KRAS, CCND2, AKT1, DICER1, TSC2, NF1, ID is common in SKS, and may be severe, moderate or mild. It could appear alone or in combination with delay or absent speech, as well as distorted articulation. 22 Baynam et al 21 Baynam et al 21 Baynam et al 21 Mroske et al 19 Mroske et al 18 Mirzaa et al 18 Mirzaa et al 18 Mirzaa et al 18 Ghahramani et al 20 Ghahramani et al 20 Moller et al 18 Mirzaa et al 18 Mirzaa et al 18 Mirzaa et al 18 Ghahramani et al 20 Ghahramani et al 20 Moller et al 17 Type of mutation
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| Molecular results
There is no clear genotype-phenotype correlation in either the 27 patients with SKS or in the 27 cases described with somatic brain alteration. The variants described are located along all exons of mTOR. However, there are some hotspots: the c.5395G>A;p. The penetrance in SKS seems to be 100% as all patients with a germline or mosaic mTOR mutation have had clinical findings; however, this may change in the future due to current ascertainment bias.
Germline mTOR mutations have been found in 92.6% (25/27) of the patients with SKS. One of the patients reported by Ghahramani, as well as Patient 2 (P2) described in this study, had constitutive, mosaic mTOR mutations, because the mutated allele was detected in low percentages in all tissues studied, including blood. Case 2 from
Ghahramani showed increased abundance of the mutant allele in the affected skin (36%) vs blood (1%). 20 In our study, Patient 2 showed by NGS the mutant allele in 2% (12/720) of the reads in blood sample, 11% (39/341) in saliva, 18% (only by pyrosequencing) in hyperpigmented skin, and 28% (76/268) in hypopigmented skin, all confirmed by pyrosequencing ( Figure 2 ).
In 9 out of 27 SKS patients (33.3%) gonadal mosaicism has been suspected. In the case of the family studied by Baynam et al, the mutation p.Glu1799Lys was transmitted in the mother's germline, as all 3 children had different fathers. 21 In the family reported by
Mroske et al, the mutation p.Glu1799Lys found in 2 siblings (of 6 and 23 years) was not detected in blood sample of either parent. 19 In the family reported by Moosa et al, high-depth sequencing of parental blood samples did not detect the presence of mosaicism for the mutation p.Glu1799Lys, which could be localized in the chromosome of paternal origin. 12 In the family described herein the mutation p.
Phe2202Cys was detected in blood samples from the 2 siblings, and
was not present in blood samples from either parent or sperm sample from the father, thus maternal gonadal mosaicism is suspected. 24 Moller et al 17 Moller et al 17 Moller et al 17 Moller et al 17 Moller et al 17 Moller et al This suggests that mutations in the FAT protein domain could increase mTOR activity by a decrease in its inhibition; still, it cannot be ruled out FIGURE 4 The PI3K/PTEN-mTOR pathway regulating cell growth and proliferation. mTOR is activated by signalling through the PI3K-Akt pathway. PTEN, TSC1, and TSC2 act as negative regulators of the mTOR pathway, and removal or loss-of-function mutations lead to hyperactivation of mTOR. mTOR complex 1 (mTORC1) signalling requires activation of the adaptor protein Raptor, and mTOR complex 2 (mTORC2), which is largely insensitive to acute rapamycin treatment, requires activation of the Rictor protein. GATOR1: GAP activity toward Rags (GATOR) complex is composed by Depdc5, Nprl2 and Nprl3. DEPDC5 along with TSC1 and TSC2, acts as a negative regulator of mTORC1. Both TSC1 and TSC2 provide critical regulation of mTORC1 through the GTPase-activating protein (GAP) activity of the TSC protein complex towards the RHEB GTPase. Similarly, the GATOR1 complex provides critical regulation of mTORC1 through its GAP activity on the Rag GTPases. Loss of either of these protein complexes through loss of any one of their critical protein components leads to high-level activation of mTORC1, and downstream effects on anabolic processes, including synthesis of all components needed for organelle synthesis, protein translation, and an increase in cell size that these mutations, as well as mutations outside the FAT domain, generate an increase of mTOR kinase activity. 30 Gonadal mosaicism, both of maternal and paternal origin, seems to be highly common in SKS (33.3%), which has implications for genetic counselling. Specifically, a relatively high recurrence risk, compared to de novo mutations, should be considered, although precise recurrence risks cannot currently be provided. A recent hypothesis proposed that the mTOR GOF mutation p.Glu1799Lys-present in the 3 families with gonadal mosaicism described then-represents a mutational hotspot in somatic cells (eg, germline and colorectal tissues) 12 . However, these figures may change in the future due to current ascertainment bias.
Germinal mutations, either de novo, inherited from affected par- epilepsy, but still needs to be tested. 32 In conclusion, SKS, caused by germline or mosaic mutations in the mTOR gene, is a recently described and clinically discernible disorder characterized mainly by ID, macrocephaly/hemi/megalencephaly, and seizures. Facial dysmorphism and other non-neurological manifestations, may also provide diagnostic clues in some individuals.
However, there is a high phenotypic overlap with other syndromes associated with the PI3K-AKTmTOR pathway (ie, MCAP). Since the best tool to make a clinical diagnosis is to think about a specific diagnostic possibility, this paper presents for the first time an in-depth review of this rare disease, which may help not only in the improvement of the clinical diagnosis but also in the diagnostic approach. We have also confirmed mosaic mTOR mutations present in all studied tissues (including blood) as a cause in SKS, which have consequences in terms of phenotype and diagnosis. Similarly, the review of all available aspects to date may also be of interest for further clinical management, follow-up, and therapeutic approaches (ie, mTOR inhibitors) on this group of patients.
